NewAmsterdam Pharma Company NV (NAMS)

NASDAQ
Currency in USD
23.670
+0.330(+1.41%)
Closed
After Hours
23.6700.000(0.00%)
NAMS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
22.76023.940
52 wk Range
15.19027.290
Key Statistics
Edit
Prev. Close
23.34
Open
23.18
Day's Range
22.76-23.94
52 wk Range
15.19-27.29
Volume
994.63K
Average Volume (3m)
814.91K
1-Year Change
5.95%
Book Value / Share
7.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAMS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
45.685
Upside
+93.01%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period
Show more

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, blocking the transfer of cholesteryl esters from HDL to LDL particles, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company NV SWOT Analysis


Obicetrapib's Promise
NewAmsterdam Pharma's lead drug candidate shows potential to revolutionize cardiovascular disease treatment, with significant LDL-C reduction and MACE benefits
Market Opportunity
Analysts project potential U.S. sales exceeding $1.3 billion, with global end-user sales opportunity surpassing $2.5 billion for obicetrapi
Patent Protection
Robust patent portfolio expected to provide market exclusivity until late 2030s, ensuring long-term revenue potential for NewAmsterdam Pharma
Analyst Outlook
Price targets range from $29.03 to $52.39, reflecting optimism in obicetrapib's potential despite challenges in regulatory approval and market adoption
Read full SWOT analysis

Compare NAMS to Peers and Sector

Metrics to compare
NAMS
Peers
Sector
Relationship
P/E Ratio
−10.8x−1.5x−0.6x
PEG Ratio
0.560.040.00
Price/Book
3.4x1.9x2.6x
Price / LTM Sales
57.1x17.9x3.0x
Upside (Analyst Target)
92.8%320.4%51.6%
Fair Value Upside
Unlock21.9%9.3%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 45.685
(+93.01% Upside)

Earnings

Latest Release
Feb 26, 2025
EPS / Forecast
-0.935 / -0.96
Revenue / Forecast
12.80M / 12.79M
EPS Revisions
Last 90 days

FAQ

What Is the NewAmsterdam Pharma (NAMS) Stock Price Today?

The NewAmsterdam Pharma stock price today is 23.67.

What Stock Exchange Does NewAmsterdam Pharma Trade On?

NewAmsterdam Pharma is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for NewAmsterdam Pharma?

The stock symbol for NewAmsterdam Pharma is "NAMS."

What Is the NewAmsterdam Pharma Market Cap?

As of today, NewAmsterdam Pharma market cap is 2.60B.

What is NewAmsterdam Pharma Earnings Per Share?

The NewAmsterdam Pharma EPS is -2.56.

What Is the Next NewAmsterdam Pharma Earnings Date?

NewAmsterdam Pharma will release its next earnings report on 06 May 2025.

From a Technical Analysis Perspective, Is NAMS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.